(IN BRIEF) AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) with EGFR mutations who have not experienced disease progression after platinum-based chemoradiation therapy. This … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Dr. Manuel Cobo, safety, Susan Galbraith, Tagrisso, therapy, Unresectable EGFR-Mutated Lung Cancer
(IN BRIEF) An international research group, led by Professor Stefan Feuerriegel from LMU, is pioneering the application of causal machine learning (ML) in medical diagnostics and therapy. Published in Nature Medicine, their study asserts that causal ML has the potential … Read the full press release
(IN BRIEF) AstraZeneca is advancing its lung cancer portfolio at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer. The company is aiming to have an AstraZeneca medicine for over half of all … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, Dave Fredrickson, FLAURA2, IASLC Conference 2023, Lung Cancer Treatments, Susan Galbraith, Tagrisso (osimertinib), therapy, World Conference on Lung Cancer (WCLC)
(IN BRIEF) A study conducted by researchers at the University of York and University of Sheffield found that common childhood phobias, such as fear of spiders, dogs, and needles, could be resolved in a single three-hour therapy session instead of … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 2-Aug-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish science-led biopharmaceutical company, has announced that its Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus … Read the full press release
Posted in Healthcare, Marketing, News, Science, Technology, United Kingdom
Tagged AstraZeneca, bronchitis, corticosteroid, cough, cutaneous lupus erythematosus, Dr. Richard Furie, FDA, herpes zoster, infusion-related reactions, lupus, lupus nephritis, Mene Pangalos, MUSE Phase II trial, myositis, nasopharyngitis, OCS, oral corticosteroid, pathophysiology of lupus, Saphnelo, SLE, systemic lupus erythematosus, therapy, TULIP Phase III trials, type I IFN, type I interferon, upper respiratory tract infection
Transformational milestone in execution of Siemens’ Vision 2020+ strategy Siemens Healthineers intends to acquire 100 percent stake in U.S. healthcare company at a purchase price of around $16.4 billion Acquisition to create global leader in cancer research and therapeutics and … Read the full press release
One week left to register for this event! (PRESS RELEASE) BERLIN, 28-May-2019 — /EuropaWire/ — The Parenteral Drug Association (PDA) is pleased to announce the speaker lineup for the 2019 PDA EU Advanced Therapy Medicinal Products: Cell and Gene Therapy … Read the full press release
Posted in France, Germany, Healthcare, Ireland, Italy, Lithuania, Media, Netherlands, News, Pharma & Biotech, Science
Tagged advanced therapy medicinal product, Alistair Gibb, ATMP, biopharmaceutical community, Cell, cell and gene therapies, Cell-Based Therapy Control Strategy, Control, GENE, GMP, Isabelle Bekeredjian-Ding, Manufacturing, medicine, Microbiological Quality Control in ATMP Manufacturing, Parenteral Drug Association, PDA, PDA EU ATMP Conference, pharmaceutical community, Romaldas Maciulaitis, The Paul-Ehrlich Institute, therapy, UK Medicines and Healthcare Products Regulatory Agency, Walter Morris
Places ICD Leads Under Rib Cage, Outside Heart and Veins DUBLIN and NICE, FRANCE, 09-Jun-2016 — /EuropaWire/ — Medtronic plc (NSYE: MDT) today announced results from several feasibility studies evaluating a new approach to implantable cardioverter defibrillator (ICD) therapy at CARDIOSTIM … Read the full press release
23-4-2013 — /europawire.eu/ — These sorts of new techniques potentially offer exciting possibilities to patients for the treatment of a range of difficult or previously untreatable conditions. Like all treatments, these techniques also come with benefits and risks. Specific rules were introduced … Read the full press release
Posted in European Union, Government, Healthcare, Law, Pharma & Biotech, Society, United Kingdom
Tagged EMA, European Medicines Agency, medicines, patients, Stem cell, Stem cell therapy, Stem cell therapy treatments, therapy, traceability of materials, treatment, treatment protocols, untreatable conditions
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
